Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO1VP9)

Drug Name

RG6179 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
uveitic macular edema	9B78	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siltuximab	DMGEATB	Anemia	3A00-3A9Z	Approved	[2]
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[3]
Olokizumab	DM4Z9QI	Rheumatoid arthritis	FA20	Phase 3	[4]
Ziltivekimab	DME841B	Heart failure	BD10-BD13	Phase 3	[5]
PF-04236921	DM826SW	Crohn disease	DD70	Phase 2	[3]
Clazakizumab	DM6ZOUV	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[3]
CDP-6038	DM3YB2C	Rheumatoid arthritis	FA20	Phase 2	[6]
ALD-518	DMPWSBL	Psoriatic arthritis	FA21	Phase 2	[6]
YSIL6	DM0K8U7	Crohn disease	DD70	Phase 2	[7]
Gerilimzumab	DMA9UX2	Rheumatoid arthritis	FA20	Phase 1	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of Roche
2	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
5	IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 May 29;397(10289):2060-2069.
6	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380)